Salarius Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Salarius Pharmaceuticals generated cash of -$12,846,137, which is more than the previous year. Cash used in financing activities reached the amount of $6,639,612 last year. Net change in cash is therefore -$6,206,525.
Cash Flow
| 2014 | 0 | 0 | 0 |
|---|---|---|---|
| 2015 | -20.74M | -27.26M | 80.84M |
| 2016 | -32.05M | -12.24M | 22.09K |
| 2017 | -27.72M | 24.48M | 2.63K |
| 2018 | -23.59M | 14.12M | 118.01K |
| 2019 | -11.58M | 5.60M | 3.57M |
| 2020 | -10.31M | -2.6K | 17.69M |
| 2021 | -10.20M | 0 | 28.29M |
| 2022 | -17.59M | -1.5M | 1.98M |
| 2023 | -12.84M | 0 | 6.63M |
SLRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.10M | 29.21M | 11.11M | 3.73M | 6.13M | 19.31M | 22.41M | 66.68M | 33.85M | 0 |
Operating activities | ||||||||||
Net income | -12.54M | -31.60M | -12.76M | -7.35M | -6.93M | -21.92M | -34.43M | -39.49M | -29.14M | 0 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 10.05K | 6.67K | 19.18K | 18.05K | 127.40K | 228.15K | 324.54K | 277.23K | 49.88K | 0 |
Stock-based compensation expense | 524.83K | 796.80K | 559.04K | 319.39K | 751.61K | 0 | 4.21M | 6.57M | 6.59M | 0 |
| Deferred income tax benefit | 524.83K | 796.80K | 559.04K | 319.39K | 751.61K | 0 | 4.21M | 6.57M | 6.59M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.48M | 0 | 2.24M | -3.85M | 690 | 7.20K | 1.79K | -12.18K | 0 | 0 |
Inventories | 0 | 0 | -2.24M | 3.85M | 1.16K | 227.97K | 22.24K | -454.13K | 0 | 0 |
Accounts payable | -2.25M | 1.31M | -310.66K | -2.78K | -519.27K | -1.66M | 819.35K | 309.43K | 621.39K | 0 |
Cash generated by operating activities | -12.84M | -17.59M | -10.20M | -10.31M | -11.58M | -23.59M | -27.72M | -32.05M | -20.74M | 0 |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -1.99M | -32.98M | -38.68M | -39.39M | 0 |
Investments In Property Plant And Equipment | -3 | -1.5M | 0 | -2.6K | 0 | 0 | -113.49K | -559.37K | -265.61K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 5.60M | 0 | 5.34K | 5.25K | 0 | 0 |
Cash generated by investing activities | 0 | -1.5M | 0 | -2.6K | 5.60M | 14.12M | 24.48M | -12.24M | -27.26M | 0 |
Financing activities | ||||||||||
Common Stock Issued | 6.92M | 1.98M | 27.28M | 14.79M | 4.13M | 118.01K | 2.63K | 22.09K | 80.44M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -133.59K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -615.01K | 0 | 0 | 0 | 0 |
Repayments of term debt | -280.91K | 0 | -477.02K | -974.43K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.63M | 1.98M | 28.29M | 17.69M | 3.57M | 118.01K | 2.63K | 22.09K | 80.84M | 0 |
Net Change In Cash | -6.20M | -17.10M | 18.09M | 7.37M | -2.39M | -9.35M | -3.23M | -44.27M | 32.83M | 0 |
Cash at end of period | 5.89M | 12.10M | 29.21M | 11.11M | 3.73M | 9.95M | 19.18M | 22.41M | 66.68M | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |